Navigation Links
Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
Date:2/5/2008

NEW YORK, Feb. 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will be presenting at the following upcoming Investor Conferences:

Thursday, February 7th, 2008 - 10:20 AM ET:

Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference
Grand Hyatt Hotel

New York City

Monday, February 11, 2008 - 12:30 PM ET:

BIO CEO & Investor Conference

Waldorf=Astoria Hotel

New York City

Each of Mr. Weiss' presentations will be webcast live and may be accessed from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of each presentation webcast will be available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide oral gelcap), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase 3 and Phase 4 clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, iron- based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
3. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
4. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
5. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
6. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
7. Nabi Biopharmaceuticals to Present at the BMO Capital Markets Focus on Healthcare Conference
8. China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals Stockholders Approve Asset Sale
10. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
11. RiskMetrics Group (ISS) and Glass Lewis & Co. Support Nabi Biopharmaceuticals Proposed Asset Sale
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... NC (PRWEB) June 19, 2013 ... eclinical commerce network for clinical trials, today announced ... at DIA 2013 (booth #2000) in Boston, June ... the industry’s first and only fully configurable, cloud-based ... ClinPay®, the flagship module within Clinverse’s eClinical Commerce ...
(Date:6/19/2013)... 19, 2013 MO BIO Laboratories, Inc., ... challenging microbial nucleic acid purification, announces the launch ... extraction of pure protein from all soil types. ... the 20 th anniversary of the company ... (Photo: http://photos.prnewswire.com/prnh/20130619/LA32633 ) ...
(Date:6/19/2013)... NineSigma , Inc., of Cleveland , ... NineSights.com is now the innovation engine for the ... of innovators. From technology developers, to chemical ... out for its large community of innovators in an ... vetted by NineSigma. The community is free to join ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Today DuPont ... young people to become leaders in the greatest challenge ... billion people in 2050. Borel spoke at the ... Conference in Atlanta, about urgent need for students to ... are local, science-based, sustainable and reached in collaboration with ...
Breaking Biology Technology:Clinverse, Inc. Exhibiting and Showcasing Its Technology at DIA 2013 2MO BIO Laboratories, Inc. launches the first kit for protein extraction from soil 2NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 2NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 3DuPont Leader Calls for New Generation of Food Visionaries to Fight Hunger 2
... U.S. Food and Drug Administration clears new implant for ... Innovations, Inc. (SBi),a single-source provider of products, technology and ... orthopedic industry, announced that its,Artelon(R) STT Spacer has been ... This product extends SBi,s line of surgically implanted, ...
... FRAZER, Pa., Sept. 21 Cephalon, Inc. (Nasdaq:,CEPH) ... Drug Application (NDA) to,the U.S. Food and Drug ... the treatment of patients with chronic,lymphocytic leukemia (CLL). ... disease with an estimated 15,000 new cases diagnosed ...
... CLARA, California, September 21, ChemAxon, a software solutions ... A ) today announced an,agreement to maintain the ... ChemAxon,s software suite. Agilent acquired,the Kalabie ELN from ... between Klee and ChemAxon to Agilent and ChemAxon. ...
Cached Biology Technology:Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis 2Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis 3Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis 4Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis 5Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 2Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 3Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 4ChemAxon and Agilent Technologies Sign Agreement Extending JChem Integration With Kalabie Electronic Lab Notebook 2
(Date:6/19/2013)... specifically for human consumption qualifies as a gluten-free cereal ... (CD), scientists have confirmed in a study published in ... , Joyce Irene Boye and colleagues point out ... States alone have CD. They develop gastrointestinal and other ... that contain gluten-related proteins. Boye,s team sought to expand ...
(Date:6/19/2013)... NEW YORK , June 19, 2013  New ... #8,461,981 by the United States Patent and Trademark Office ... security systems that reflect whether guards have been injured, ... of an extensive portfolio under the Intellectual Properties Agreements ... Lisa Pamintuan , President of New ...
(Date:6/19/2013)... to contribute to a very large and potentially record-setting ... University of Michigan ecologist and colleagues who released their ... Bay. , The Gulf forecast, one of two announced ... an oxygen-depleted, or hypoxic, region of between 7,286 and ... 10 largest on record. , The low end of ...
Breaking Biology News(10 mins):New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 3New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 4U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 2U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 3U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 4
... Earth Observatory of Singapore (EOS) which aspires to ... addressing several of civilisation,s most serious environmental threats ... change aims to provide invaluable research and ... could potentially save hundreds of thousands of lives. ...
... determining ways to speed the return of residents to ... The first step is providing better, more accessible ... architects and others says Dr. Dave Tilotta, associate professor ... first part of a multi-phase study examining the resilience ...
... Hopkins engineer is trying to coax human stem cells ... could someday be used to replace damaged tissue in ... Sharon Gerecht, an assistant professor of chemical and molecular ... received a $150,000 two-year grant from the March of ...
Cached Biology News:The Earth Observatory of Singapore devoted to the study of earth sciences officially opens 2The Earth Observatory of Singapore devoted to the study of earth sciences officially opens 3Defying the disaster: Researcher explores resilient housing 2Researcher seeks to turn stem cells into blood vessels 2Researcher seeks to turn stem cells into blood vessels 3
ANTI MYCOBACTERIUM TUBERCULOSIS...
IMAGEQUANT 100 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
ImageQuant 100 UV, 1 EA. Category: ImageQuant CCD Imagers....
The FlowTACS Apoptosis Detection Kit is designed specifically for in situdetection of apoptotic...
Biology Products: